Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01405950 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy
A Phase 1 study, sponsored by Acorda Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01405950 is a Phase 1 study that was terminated before completion, run by Acorda Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT01405950, a Phase 1 study, was terminated before completion, sponsored by Acorda Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
A Single-Dose, Phase 1b, Multicenter, Open-Label Study to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in Pediatric Subjects 2 to 16 Years Old With Mild to Moderate Spasticity Due to Cerebral Palsy.
Interventions
- DRUG Zanaflex Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01405950
The ClinicalTrials.gov registry entry for NCT01405950 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zanaflex Capsules is the first listed.
NCT01405950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01405950 about?
NCT01405950 is a clinical study titled "Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy". A Single-Dose, Phase 1b, Multicenter, Open-Label Study to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in Pediatric Subjects 2 to 16 Years Old With Mild to Moderate Spasticity Due to Cerebral Palsy.
What is the current status of trial NCT01405950?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2011-05. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01405950?
The interventions under investigation include: Zanaflex Capsules (DRUG).
Who is sponsoring clinical trial NCT01405950?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.